We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App





Expanded Steroid Control Launched at the 2015 AACC Annual Meeting

By LabMedica International staff writers
Posted on 30 Jul 2015
Expanded Steroid Control has been launched that now contains nine analytes of interest at clinically relevant levels for mass spectrometry and separation science technology. More...


The nine analytes included in the specialty matrix are Corticosterone, Cortisol, Cortisone, Dehydroepiandrosterone (DHEA), Progesterone, 17α-Hydroxyprogesterone, Testosterone, with the addition of Androstenedione and 11 Deoxycortisol.

The Expanded Steroid Control is manufactured by UTAK (Valencia, CA, USA) within its proprietary SMx Serum Specialty Matrix. For use with any methodology, UTAK's stock and custom quality controls are handcrafted and sold to Clinical, Toxicology and Esoteric laboratories globally. UTAK's Expanded Steroid Control in SMx Serum, is offered in individual packs for Levels 1, 2, 3, 4 and a Negative Control. The International Organization for Standardization (ISO) accreditation guidelines note that independent third party quality controls should be used instead of, or in addition to, any control materials supplied by the reagent or instrument manufacturer. UTAK offers hundreds of stock and custom serum, whole blood, urine and oral fluids controls for use with any methodology, on any testing platform.

Jim Plutchak, CEO of UTAK, said, “Our goal is always to craft Quality Controls for Clinical and Esoteric laboratories that are as close to a human matrix as possible. Due to the issue of endogenous steroid levels in serum-based matrix products, we developed a Steroids Control in our SMx Specialty Matrix. The result is a third party control that esoteric laboratories can depend on for their laboratory developed tests.” Charles E. Pippenger, PhD, adjunct professor Department of Neurosciences, University of Vermont College of Medicine added, “Inter-laboratory comparison of results, made possible with a uniform control, allows labs to be confident that test results generated are accurate.”

The Expanded SMx Steroid Control was released at the 2015 American Association of Clinical Chemistry (AACC) Meeting & Clinical Lab Expo held July 26–30, in Atlanta (GA, USA).

Related Links:
UTAK
University of Vermont College of Medicine 
American Association of Clinical Chemistry  



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Manual Pipetting Aid
Pipette Controllers macro
New
Drug Testing Assays
Atellica DT 250 Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image Credit: iStock

Prehospital Blood Test Could Reduce Emergency Transfers for Chest Pain

Chest pain leads to ambulance transport to an emergency department for about 95% of patients, although only a minority have a serious cardiac condition. Troponin testing helps assess heart muscle damage,... Read more

Molecular Diagnostics

view channel
Image: The method combines metagenomic sequencing with computational filtering to identify likely disease-causing bacteria and viruses (Image Credit: iStock)

Computational Filters Enhance Metagenomic Detection of Meningitis and Encephalitis

Infections of the central nervous system, such as meningitis and encephalitis, can be severe and require prompt diagnosis and treatment. Clinicians typically evaluate cerebrospinal fluid alongside symptoms... Read more

Immunology

view channel
Image: Aptiva utilizes particle-based multi-analyte technology (PMAT) (Photo courtesy of Werfen)

Werfen Expands Automated APS Testing with FDA-Cleared and CE-Marked IgA Reagent

Antiphospholipid syndrome (APS) is an autoimmune disorder associated with thrombosis and pregnancy complications, but its symptoms can overlap with those of other conditions, complicating diagnosis.... Read more

Microbiology

view channel
Image: RealTime Labs’ Mycotoxin Extensive Panel measures 31 mold-related toxins across seven toxin classes from a single urine sample (Photo courtesy of RealTime Labs)

New Urine Test Expands Mycotoxin Analysis to 31 Markers for Broader Exposure Assessment

Clinical evaluation of mold exposure increasingly relies on urinary mycotoxin testing, but limited marker coverage and metabolite masking can make results more difficult to interpret. Broader analysis... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.